Valor Medical And Its Top Execs Plead Guilty To Concealing Device Toxicity From FDA

Valor Medical and 4 of its top brass admit to concealing required data from FDA regulators while undergoing review for an aneurysm treatment implant. California biotech company Valor Medical, 4 executives and a consultant admitted to the Dept. of Justice that they concealed information about their Neucrylate diagnostic assay, hiding toxicity reports that were required as the product was undergoing FDA premarket review. Valor pled guilty to felony charges of failing to provide required information and was ordered to pay $250,000 at a rate of $50,000 per year, with the 1st payment due last month.